Previous studies have demonstrated that CCL20 is markedly upregulated in autoimmune disorders such as inflammatory bowel disease (IBD) and arthritis, and anti-CCL20 antibodies have shown efficacy in ameliorating symptoms in clinical trials [45,47]. Here, CCL20 is linked to arthritic joint disease.